超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

泰邦生物集團 China Biologic Products 中國生物制品  
China Biologic Products, Inc. (NASDAQ: CBPO) 是國家承認的最大的非國有血漿生物醫藥制品公司，通過我們旗下的山東泰邦生物制品有限公司、貴陽大林生物科技公司，以及我們投資于西安回天血液制品的產品，我們已經成為了血漿生物醫藥制品行業的綜合供應商，我們有能力跨越，以從血漿存儲，到研究發展，到產品制造和全面商業化。我們的主要產品，人類血蛋白和免疫球蛋白，最常被用于治療威脅生命的各種情況，如低白蛋白，血友病及其他血液病。我們目前有20個銷售血漿產品和新產品的生產線，以推動大中國市場未來的血液產品市場的發展。為了配合我們的有機增長，我們繼續尋求戰略收購機會，擴大我們在中國地區的血漿儲備能力，并加強我們的研發和技術上的能力。

China Biologic Products Inc。泰邦生物是一家在納斯達克交易所上市的公司，股票代碼CBPO，公司總部設于中國北京市。泰邦生物是最大的的非國有制的血漿生物醫藥制品公司，旗下擁有子公司山東泰邦生物制品有限公司，貴陽大林生物科技公司，以及西安回天血液制品公司的股份，我們已經成為了在血漿收集、開發和生產新的血液藥物、并將其終端產品商品化的綜合供應商。我們的產品主要針對緊急醫療情況，以及預防和治療威脅生命的疾病。我們的產品在的終端用戶是醫院和其他衛生保健機構。

China Biologic Products, Inc. (Nasdaq: CBPO), is one of the China’s largest non-state-owned fully integrated plasma-based biopharmaceutical companies. Our products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases that include rabies, tetanus, and hepatitis B.

Our core capabilities include plasma collection, research and development, production, and commercialization of biopharmaceutical products.

Currently we produce more than 20 plasma-based products and have a pipeline of new and developing products to drive our future in China’s growing plasma market. To complement our organic growth, we consider acquisitions to expand our plasma collection capabilities in China. We are constantly at work to enhance our R&D and technological capabilities to create new products and to improve our existing products and processes.

We sell directly to hospitals and other healthcare facilities in China and are reducing the use of independent distributors.

Our headquarters is in the city of Beijing. We manufacture in our indirect majority-owned subsidiaries, Shandong Taibang Biological Products and Guiyang Dalin Biologic Technologies, and have an equity investment in Xi’an Huitian Blood Products.